Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer

The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.

Participants needed: 200
Trial details
Age: 18+Biological sex: FemaleType: ObservationalSponsor: Institut fuer FrauengesundheitUpdated: May 14, 2026Locations: 1
Eligibility criteria

Femal patients age 18 or older at time of informed consent [+3]

Locally advanced or metastatic breast cancer [+2]

Status: Not yet recruiting

IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE

The goal of this interventional study is to evaluate the effect of standardized patient coaching on treatment adherence among patients taking abemaciclib. The main question it aims to answer is, whether standardized coaching leads to patients taking abemaciclib much more consistently. Researchers will therefore compare therapy adherence of patients receiving standardized coaching to patients receiving routine care. Participants will be asked to answer several questionnaires.

Participants needed: 257
Trial details
Biological sex: FemaleType: InterventionalSponsor: Institut fuer FrauengesundheitUpdated: Apr 9, 2026Locations: 1
Eligibility criteria

Women age 18 or older at time of ICF signature [+3]

Women who are pregnant or lactating [+2]

Status: Recruiting

Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

This is a single-arm, open-label phase IV study of patients with advanced HR+/HER2- breast cancer who are treated first line with ribociclib and standard of care endocrine treatment according to SmPC.

Participants needed: 1,000
Trial details
Phase: Phase 4Age: 18+Biological sex: FemaleType: InterventionalSponsor: Institut fuer FrauengesundheitUpdated: Apr 18, 2023Locations: 52
Eligibility criteria

Indication for treatment with ribociclib in combination with endocrine therapy i... [+9]

Concurrent participation in a study with an investigational agent/device or with... [+11]